Visceral Adiposity and Neutralizing Antibody Expression: An Adult-Based Cross-Sectional Study.
Huanhuan Wang1, Dan Xiao2, Hua Zhou3
1School of Laboratory Medicine, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China.
Journal of Inflammation Research
|September 2, 2024
Summary
High Chinese visceral adiposity index (CVAI) may reduce SARS-CoV-2 vaccine effectiveness by lowering neutralizing antibodies. This suggests targeted vaccination strategies for individuals with high CVAI are needed to enhance COVID-19 protection.
Area of Science:
- Immunology
- Public Health
- Epidemiology
Background:
- Visceral adiposity is a known risk factor for severe COVID-19.
- The impact of the Chinese visceral adiposity index (CVAI) on SARS-CoV-2 vaccine efficacy is not well understood.
Purpose of the Study:
- To investigate how CVAI affects neutralizing antibody (NAb) production after inactivated SARS-CoV-2 vaccination.
- To explore the underlying mechanisms and optimize vaccination strategies.
Main Methods:
- A cross-sectional study of 206 vaccinated health workers.
- Collected anthropometric data, immune cell counts, inflammatory cytokines, and NAb titers.
- Calculated CVAI and divided participants into reference and dysfunction groups.
Main Results:
- Lower NAb titers were observed in the high CVAI group compared to the reference group.
- High CVAI correlated with increased hsCRP, monocytes, lymphocytes, and B-lymphocytes, and decreased NAb titers.
- The overall vaccine efficacy was 87.86% with a median NAb titer of 12.94 AU/mL.
Conclusions:
- CVAI may impair SARS-CoV-2 NAb production by promoting immune dysfunction and chronic inflammation.
- Vaccination strategies should consider individuals with high CVAI to improve COVID-19 vaccine effectiveness.
- These findings support enhanced COVID-19 prevention and control measures.
